title: [New trends of acid-related diseases treatment].
abstract: Acid-related diseases (ARD) including gatroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) are treated by acid suppression drugs, especially proton pump inhibitor (PPI). Use of PPI as a first line therapy for ARD is recommended in various guidelines. Recently, vonoprazan, a new class of acid secretion inhibitor called potassium-competitive acid blocker (P-CAB) developed in Japan for the treatment of ARD. The drug is covered by the Japanese medical insurance for the treatment of ARD, and it is reported that Helicobacter pylori (HP) eradication rate with it is more than 90%.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Koike
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kanno
authors.forename: Katsunori
authors.initials: K
authors.lastname: Iijima
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D054328:Proton Pump Inhibitors; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19